Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 472

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Open access
Hong, Theodore S., Wo, Jennifer Y., Yeap, Beow Y., Ben-Josef, Edgar, McDonnell, Erin I., Blaszkowsky, Lawrence S., Kwak, Eunice L., Allen, Jill N., Clark, Jeffrey W., Goyal, Lipika, Murphy, Janet E., Javle, Milind M., Wolfgang, John A., Drapek, Lorraine C., Arellano, Ronald S., Mamon, Harvey J., Mullen, John T., Yoon, Sam S., Tanabe, Kenneth K., Ferrone, Cristina R., Ryan, David P., DeLaney, Thomas F., Crane, Christopher H., Zhu, Andrew X.·2016·Journal of Clinical Oncology

Abstract

Purpose: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Materials and Methods: In this single-arm, phase II, multi-institutional study, 92 patients with biopsy-confirmed HCC or ICC, determined to be unresectable by multidisciplinary review, with a Child-Turcotte-Pugh score (CTP) of A or B, ECOG performance status of 0 to 2, no extrahepatic disease, and no prior radiation received 15 fractions of proton therapy to a maximum total dose of 67.5 Gy equivalent. Sample size was calculated to demonstrate > 80% local control (LC) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria at 2 years for HCC patients, with the parallel goal of obtaining acceptable precision for estimating outcomes for ICC. Results: Eighty-three patients were evaluable: 44 with HCC, 37 with ICC, and two with mixed HCC/ICC. The CTP score was A for 79.5% of patients and B for 15.7%; 4.8% of patients had no cirrhosis. Prior treatment had been given to 31.8% of HCC patients and 61.5% of ICC patients. The median maximum dimension was 5.0 cm (range, 1.9 to 12.0 cm) for HCC patients and 6.0 cm (range, 2.2 to 10.9 cm) for ICC patients. Multiple tumors were present in 27.3% of HCC patients and in 12.8% of ICC patients. Tumor vascular thrombosis was present in 29.5% of HCC patients and in 28.2% of ICC patients. The median dose delivered to both HCC and ICC patients was 58.0 Gy. With a median follow-up among survivors of 19.5 months, the LC rate at 2 years was 94.8% for HCC and 94.1% for ICC. The overall survival rate at 2 years was 63.2% for HCC and 46.5% ICC. Conclusion: High-dose hypofractionated proton therapy demonstrated high LC rates for HCC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.64.2710

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 472

Metadata

Authors
Hong, T. S., Wo, J. Y., Yeap, B. Y., Ben-Josef, E., McDonnell, E. I., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., Murphy, J. E., Javle, M. M., Wolfgang, J. A., Drapek, L. C., Arellano, R. S., Mamon, H. J., Mullen, J. T., Yoon, S. S., Tanabe, K. K., Ferrone, C. R., Ryan, D. P., DeLaney, T. F., Crane, C. H., & Zhu, A. X.
Venue
Journal of Clinical Oncology
Published
2016-02-10
Volume
34
Issue
5
Pages
460-468
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2198248975
Cited by
472
References
15
FWCI
18.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. https://app.cochat.ai/papers/10.1200/jco.2015.64.2710
The paper
Hong, T. S., Wo, J. Y., Yeap, B. Y., Ben-Josef, E., McDonnell, E. I., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., Murphy, J. E., Javle, M. M., Wolfgang, J. A., Drapek, L. C., Arellano, R. S., Mamon, H. J., Mullen, J. T., Yoon, S. S., Tanabe, K. K., . . . Zhu, A. X. (2016). Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.64.2710

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.